Talmage J Raine, MD in Urbana, IL - Plastic Surgery

Talmage J Raine, MD is a Plastic Surgery physician based in Urbana, Illinois. Talmage J Raine is licensed to practice in Illinois (license number 36-057908) and his current practice location is 1405 W Park St, Ste 206, Urbana, Illinois. He can be reached at his office (for appointments etc.) via phone at (217) 366-2650.

NPI number for Talmage J Raine is 1902912678 and his current mailing address is 1405 W Park St, Ste 206, Urbana, Illinois. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1902912678.

Contact Information

	Talmage J Raine, MD
	1405 W Park St, Ste 206, Urbana, IL 61801-2365
	(217) 366-2650
	(217) 366-2652

Physician's Profile

Full Name	Talmage J Raine
Gender	Male
Speciality	Plastic Surgery
Location	1405 W Park St, Urbana, Illinois
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1902912678
Provider Enumeration Date: 08/22/2006
Last Update Date: 08/12/2015

Medical Identifiers

Medical identifiers for Talmage J Raine such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1902912678	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208200000X	Plastic Surgery	36-057908 (Illinois)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Talmage J Raine is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Talmage J Raine, MD 1405 W Park St, Ste 206, Urbana, IL 61801-2365 Ph: (217) 366-2650	Talmage J Raine, MD 1405 W Park St, Ste 206, Urbana, IL 61801-2365 Ph: (217) 366-2650

News Archive

Virtual tissue technology helps identify new drug target to combat polycystic kidney disease

Using virtual tissue technology, researchers at Indiana University have identified a potential new drug target in the fight against polycystic kidney disease, an illness with no effective FDA-approved treatment that affects 200,000 people per year in the United States.

Experimental Ebola vaccine offers high protection against deadly virus, reveals major trial

An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to results published today in The Lancet. The vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.

New paper-based sun-exposure sensor may help people stay safe

Summer is around the corner - time for cookouts and sunbathing. But too much sun can result in sunburn, which is the main cause of skin cancer. Because the time it takes to get burned depends on many factors, it is not easy to tell when to seek shade.

Calistoga Pharmaceuticals presents CAL-101 PI3K inhibitor data at European Hematology Association Congress

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today presented preclinical and clinical data on CAL-101, the Company's oral, delta selective PI3K inhibitor at the 15th Congress of the European Hematology Association in Barcelona, Spain.

New test determines which children with malaria are likely to develop cerebral malaria

Researchers at Michigan State University have identified a test that can determine which children with malaria are likely to develop cerebral malaria, a much more life-threatening form of the disease.

Talmage J Raine, MD - Plastic Surgery in Urbana, IL